Preview

Пульмонология

Расширенный поиск

Легочные побочные действия, вызываемые антиревматическими препаратами

Полный текст:

Об авторах

Ю. В. Муравьев
Институт ревматологии РАМН
Россия

Москва



И. А. Удельнова
Институт ревматологии РАМН
Россия

Москва



Список литературы

1. Княжеская Н.П. Аспириновая бронхиальная астма. Рус. мед. журн. 1998; 6 (23): 1478-1481.

2. Кристал Р.Дж. Интерстициальные заболевания легких. В кн.: Браунвальд Е., К.Дж. Иссельбахер, Р.Г. Петередорфа и др. (ред.) Внутренние болезни: Пер. с англ. М.: Медицина; 1995; кн. 6: 146.

3. Aglas R., Rainer F., Hermann J. et al. Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthr. and Rheum. 1995; 38: 291-292.

4. Alarcon G.S., Gispen J.G., Koopman W.J. Severe reversible interstitial pneumonitis induced by low dose methotrexate (letter). J. Rheumatol. 1989; 16: 1007-1008.

5. Anderson R.J., Potts D.E., Gabow P.A. et al. Unrecognized adult salicylate intoxication. Ann. Intern. Med. 1986; 85: 745-748.

6. Austr. ADR Bull. 1995; 14: 1. Цит. по: Безопасность лекарств. Экспресс-информ. 1997; 1: 15-16.

7. Averbuch М., Halpern Z., Hallak A. et al. Sulfasalazine pneumonitis. Am. J. Gastroenterol. 1985; 80: 343-345.

8. Barrera P., van Ede A., Laan R.F. et al. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of cases in a period of three months. Ann. Rheum. Dis. 1994; 53: 479-480.

9. Bedrossian C.W.M., Miller W.C., Luna M.A. Methotrexateinduced diffuse interstitial pulmonary finrosis. South. Med. J. 1979; 72: 313-318.

10. Bekerman C., Hoffer P., Betran J., Guipta R. Gallium-67 citrate imaging studies of the lung. Semin. Nucl. Med. 1980; 3: 286-301.

11. Bell M.J., Geddie W.R., Gordon D.A., Reynolds W.J. Preexisting lung disease in patients with rheumatoid arthritis may predispose to methotrexate lung (abstract). Arthr. and Rheum. 1986; 29 (suppl. 4): S75.

12. Briggs W.A., Johnson J.P., Teichman S et al. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine (Baltimore) 1979; 58: 348.

13. Broderick T.V., Reinke R.T, Goldman E. Salicylate-induced pulmonary edema. Am. J. Roentgenol. 1976; 127: 865-866.

14. Buron G.H. Rash and pulmonary eosinphillia associated with fenbufen. Br. Med. J. 1990; 300: 82-83.

15. Buscaglia A.J., Cowden F., Brill H. Pulmonary infiltrates associated with naproxen. J.A.M.A. 1984; 251: 65-66.

16. Cannon G.W., Ward J.R., Clegg D.O. et al. Acute lung disease associated with low-dose pulce methotrexate therapy in patients with rheumatoid arthritis. Arthr. and Rheum. 1983; 26: 1269-1274.

17. Cannon G.W., Reading J.C., Ward J.R. et al. Clinical and laboratory outcomes during the treatment of rheumatoid arthritis with methotrexate. Scand. J. Rheumatol. 1990; 19: 285-294.

18. Carroll G.J., Thomas R., Phatouros C.C. et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J. Rheumatol. 1994; 21: 51-54.

19. Chuck A.J., Wilcox M., Bossingham D.H. Fenbufen-associated pnemonitis. Br. J. Rheumatol. 1985; 24: 302-305.

20. Cook N.J., Carroll G.J. Successful réintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann. Rheum. Dis. 1992; 51: 272-274.

21. Cooke N .T., Bamji A.N . Gold and pulmonary function in rheumatoid arthritis. Br. J. Rheumatol. 1983; 22: 18-21.

22. Cooper J.A.D., White D.A., Matthay R.A. State of the art: Drug-induced pulmonary disease. Part 1. Cytotoxic drugs. Am. Rev. Respir. Dis. 1986; 133: 321-340.

23. Cooper A.D., White D.A., Matthay R.A. Drug induced pulmonary disease. Part 2. Non-cytotoxic drugs. Ibid. 488-505.

24. Costabel U., Schmitz-Schumann M., Guzman J. et al. Goldinduced fibrosing alveolitis. Dtsch. Med. Wschr. 1985; 110: 1162-1166.

25. Davies D., MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185-188.

26. Declauux B., Whitelaw W.A., Derenne J.P. Methotrexate and asthma (letter). Chest 1993; 103: 1307-1308.

27. Elasser S., Dalquen P., Soler M., Perruchoud A.P, Methotrexate-induced pneumonitis: appearance four weeks after discontinuation of treatment. Am. Rev. Respir. Dis. 1989; 140: 1089-1092.

28. Engelbrecht J.A., Calhon S.L., Sheerer J.J. et al. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthr. and Rheum. 1983; 26: 1275-1278.

29. Epier G.R., Snider G.L., Gaensler E.A. et al. Bronchiolitis and bronchitis in connective tissue disease. A possible relationship to the use of penicillamine. J.A.M.A. 1979; 242: 528-532.

30. Evans R.B., Ettensohn D.B. Fawaz-Estrup F. et al. Gold lung: Recent developments in pathogenesis, diagnosis, and therapy. Semin. Arthr. Rheum. 1987; 16: 196-205.

31. Fein M. Sulindac and pneumonitis. Letter. Ann. Intern. Med. 1981; 95: 245.

32. Fink S.D., Kremer J.M. Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J. Rheumatol. 1995; 22: 967-969.

33. Frank S .T., Weg J.G., Harkleorad L.E., Fitch R.F. Pulmonary disfunction in rheumatoid disease. Chest 1973; 63: 27-33.

34. Furst D.E., Ericson N., Clute L. et al. Adverse experience with methotrexate during 176 weeks of a long term prospective trial in patients with rheumatoid arthritis. J. Rheumatol. 1990; 17: 1628-1635.

35. Garcia J.G .N ., Munim A., Nugent K.M. et al. Alveolar macrophage gold retention in rheumatoid arthritis. Ibid. 1987; 14: 435-438.

36. Geddes D.M., Corin B., Brewerton D.A. et al. Progressive airway obliteration in adults and association with rheumatic disease. Quart. J. Med. 1977; 184: 427-444.

37. Golden M .R., Katz R.S., Balk R.A., Golden H.E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J. Rheumatol. 1995; 22: 1043-1047.

38. Gonzales E.B., Truslow W., Miller S.B ., Agudelo C.A. Smoking and underlying lung disease are not contraindications to methotrexate therapy (abstract). Arthr. and Rheum. 1993; 36 (suppl.9): S81.

39. Gosink B.B., Freidman P.J., Liebow A.A. Bronchiolitis obliterans. Roentgenologic-pathologic correlation. Am. J. Roentgenol. 1973; 117: 816-832.

40. Green L., Schattner A., Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of case and review of literature. J. Rheumatol. 1988; 15: 110-112.

41. Hargreaves M .R., Movat A.G., Benson M.K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992; 47: 628-633.

42. Hassan W., Carpenter M ., Kelly C. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis (letter). Ibid. 1993; 48: 191.

43. Hasselrnann M., Maurier F., Lutun P.H. et al. Syndrome de goodpasture au cours d'une polyarthrite rheumatoide par la dpenicillamine. Rev. Med. Int. 1982; 70: 237-238.

44. Heffner J.E., Sahn S.A. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann. Intern. Med. 1981; 95: 405-409.

45. Howard-Lock H.E., Lock C.J.L., Meura A. et al. D-penicillamine: Chemistry and clinical use in rheumatoid disease. Semin. Arthr. Rheum. 1986; 15: 261-281.

46. Hrnicek G., Skelton J., Miller W.C. Pulmonary edema and salicylate intoxication. J.A.M.A. 1974; 230: 866-867.

47. Hyland R.H., Gordon D.A., Broder I. et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J. Rheumatol. 1983; 10: 395-405.

48. Jansen H.M., Elema J.D., Hylkema B.S. et al. Progressive obliterative bronchiolitis in a patient with rheumatoid arthritis. Eur. J. Respir. Dis. 1982; 63 (suppl.121): 43-52.

49. Jones G., Mierins E., Karish J. Methotrexate-induced asthma. Am. Rev. Respir. Dis. 1991; 143: 179-181.

50. Juhl J.H. Paul and Juhl's essentials of roentgen interpretation. Philadelphia: Harper & Row Publishers Inc.; 1981. 988-989.

51. Kaplan R.L., Waite D.H. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch. Dermatol. 1978; 114: 1800-1802.

52. Katzenstein A.A., Askinn F.B. Surgical pathology of non-neoplastic lung disease. Philadelphia: W.B.Saunders; 1982. 108-112.

53. Kerstens P.J.S.M., van Loenhout J.W.A., Boerbooms A.M .T. et al. Methotrexate, pneumonitis, and infection (letter). Ann. Rheum. Dis. 1992; 51: 1179.

54. Khalil H., Molinary E., Stoller J.K. Diclofenac (Voltaren)- induced eosinophilic pneumonitis. Arch. Intern. Med. 1993; 153: 1649-1652.

55. Kremer J.M., Petrillo G.F., Hamilton R.A. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J. Rheumatol. 1995; 22 (l): 38-40.

56. Kremer J.M., Alarcon G.S., Weinblatt M.E. et al. Clinical, laboratory, radiographic and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis. Arthr. and Rheum. 1997; 40 (10): 1829-1837.

57. Kudo K., Miyamoto J., Horruchi Y. One case of pulmonary fibrosis occurring during therapy and a review of the chest x-rays of asthmatic patients. Jpn J. Thorac. Dis. 1977; 15: 646-652.

58. Law K.F., Aranda C.P., Smith R.L. et al. Pulmonary cryptococcosis mimicking methotrexate pneumonitis. J. Rheumatol. 1993; 20: 872-873.

59. Leduc D., De Vuyst P., Lhereux P. et al. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis: discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993; 104: 1620-1623.

60. Lee R.P., King E.G., Russel A.S. lbuprofen: A severe systemic reaction. Can. Med. Assoc. J. 1983; 29: 854-855.

61. Leino R., Liippo K., Ekfors T. Sulfasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. J. Intern. Med. 1991; 229: 553-556.

62. Levinson M .L., Lynch J.P., Bower J.C. Reversal of progressive, life threatening gold hypersensitivity pneumonitis by corticosteroids. Am. J. Med. 1981; 71: 908-912.

63. Line B.R., Hunninghake G.W., Keogh B.A. et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis; correlation with clinical studies, pulmonary function studies and bronchoalveolar lavage. Am. Rev. Respir. Dis. 1981; 123: 440-446.

64. Lippmann M. Pulmonary reactions to drugs. Med. Clin. N. Am. 1977; 61: 1353-1367.

65. Louie S., Gamble C.N., Cross C.E. Penicillamine-associated pulmonary hemmorrhage. J. Rheumatol. 1986; 13: 963-966.

66. Louie S., Lilington G.A. Low dose methotrexate pneumonitis in rheumatoid arthritis. Thorax 1986; 41: 703-704.

67. McCormick J.N., Wood P., Bell D. Penicillamine-induced Goodpasture's syndrome. In: Penicillamine research in rheumatoid disease. Oslo: Fabritius and Sonner; 1977. 132-138.

68. McKendry R.J.R., Cyr M. Toxiticy of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case control of 131 patients. Arch. Intern. Med. 1989; 149: 685-689.

69. Moseley R.H., Barwick K.W., Dobuler K., DeLuca V.A.Jr. Sulfasalazine-induced pulmonary disease. Dig. Dis. Sci. 1985; 30: 901-914.

70. Mulhierin D., Cummiskey J.M., Doyle G.D., Fitzgerald O. Methotrexate pneumonitis in rheumatoid arthritis — a dramatic response to treatment. Br. J. Rheumatol. 1992; 31: 356-357.

71. Murphy K.C., Atkins C.J., Offer R.C. et al. Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicilamme. Arthr. and Rheum. 1981; 24: 557-560.

72. Nader D.A., Schillaci R.F. Pulmonary infiltrates with eosinophilia to naproxen. Chest 1983; 83: 280-282.

73. Newman E.D., Harrington T.M. Fatal methotrexate pneumonitis in rheumatoid arthritis (letter). Arthr. and Rheum. 1988; 31: 1585-1586.

74. Park G.D., Spector R., Headstream T., Goldberg M. Serious adverse reactions associated with sulindac. Arch. Intern. Med. 1982; 142: 1292-1294.

75. Partanen J., van Assendelft A.H .W ., Koskimies S. et al. Patients with rheumatoid arthritis and gold-induced pneumonitis express two high-risk mayor histocompatibility complex patterns. Chest 1987; 92: 277-281.

76. Peces R., Riesa J.R., Arboleya L.R. et al. Goodpasture's syndrome in patient receiving penicillamine and carbamimle. Nephron 1987; 45: 316-320.

77. Perruquet J.L., Harrington T.M., Davis D.E. Pneumocystis carnii pneumonia following methotrexate therapy for rheumatoid arthritis (letter). Arthr. and Rheum. 1983; 26: 1291-1292.

78. Pourel J., Guillemin F., Fener P. et al. Delayed methotrexate pneumonitis in rheumatoid arthritis (letter). J. Rheumatol. 1991; 18: 303-304.

79. Reid J., Watson P.D., Sproull D.H. The mode of action of salicylate in acute rheumatic fever. Quart. J. Med. 1950; 19: 1-19.

80. Ridley M.G., Wolfe C.S., Mathews J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann. Rheum. Dis. 1988; 47: 784-788.

81. Roenigk H.H., Auerbach R., Maibach H.I., Weinstein G.D. Methotrexate guidelines-revised. J. Am. Acad. Dermatol. 1982; 6: 145-155.

82. Rosenow E.C. The spectrum of drug-induced pulmonary disease. Ann. Intern. Med. 1972; 77: 977-991.

83. Savihalti M. Pulmonary complications following the use of gold salts, Ann. Med. Interne Fen. 1948; 37: 263-266.

84. Schwartz G.F., Richter C., Bauerfeind S., Gross W.L. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997; 52: 377-319.

85. Schwartz G.F., Anderson S.T. Methotrexate induced pneumonitis in a young woman with psoriasis and rheumatoid arthritis (letter). J. Rheumatol. 1990; 17: 980.

86. Scott D.L., Bradby G.V.H., Altman T.J. et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann. Rheum. Dis. 1981; 40: 136-141.

87. Scully C.J., Andersen C.J., Cannon G.W. Long-term methotrexate therapy for rheumatoid arthritis. Semin. Arthr. Rheum. 1991; 20: 317-331.

88. Searles G., McKendry J.R. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and review of the literature. J. Rheumatol. 1987; 14: 1164-1171.

89. Sheehan N.J. Pulmonary infiltrates and eosonophilia associated with naproxen. Br. J. Rheumatol. 1985; 24: 302-305.

90. Shettar S.P., Chattupadhyay C., Wolstenholme R.J. et al. Diffuse alveolitis on a small dose of penicillamine. Ibid. 1984; 23: 220-224.

91. Singerland R., Hoogsteden H.C., Adriaansen H.J. et al. Goldinduced pneumonitis. Respiration 1987; 52: 232-236.

92. Smith F.E., Lindberg P.J. Life-threatening hypersensitivity to sulindac. J. A. M. A. 1980; 244: 269-270.

93. Sostman H.D., Mathay R.A, Putman C.T. et al. Methotrexateinduced pneumonitis. Medicine (Baltimore) 1976; 55: 371-388.

94. Sprung D.J. Sulifidac causing a hyersensitivity reaction with peripheral and mediastinal lymphadenopathy. Ann. Intern. Med. 1998; 97: 564.

95. Stemlieb I., Fisher М ., Scheinberg I.H. D-penicillamineinduced Goodpasture's syndrome in Wilson's disease. Ibid. 1983; 82: 673-676.

96. Stenger A.A., Houtman F.M., Bruyn G.A. et al. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand. J. Rheumatol. 1994; 23: 51-53.

97. Sullivan S.N . Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. J. Clin. Gastroenterol. 1987; 9: 461-463.

98. Takimoto C.H., Lynch D., Stulberg M .S. Pulmonary infiltrates associated with sulindac therapy. Chest 1990; 97: 230-232.

99. Thomas P., Seaton A., Edvards J. Respiratory disease due to sulphasalazine. Clin. Allergy 1974; 4: 41-47.

100. Thurston J.G., Marks P., Trapnel D. Lung changes associated with phenylbutasone treatment (letter). Br. Med. J. 1976; 2: 1422-1423.

101. Van der Veen M.J., Dekker J.J., Diant J.D. et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J. Rheumatol. 1995; 22: 1766-1768.

102. Weber J.C.P., Essigmen W.K. Pulmonary alveolitis and NSAID-fact or fiction? (letter). Br. J. Rheumatol. 1986; 25: 5-6.

103. Weinblatt M.E., Coblin J.C., Fox D.A. et al. Efficacy of lowdose pulse methotrexate in rheumatoid arthritis. N. Engl. J. Med. 1985; 312: 118-122.

104. Weinstein A., Marlowe S., Korn J. et al. Low dose methotrexate treatment of rheumatoid arthritis. Long-term observations. Am. J. Med. 1985; 79: 331-337.

105. Winterbauer R.H., Wilske K.R., Wheelis R.F. Diffuse pulmonary injury associated with gold treatment. N. Engl. J. Med. 1976; 294: 919-921.

106. Wollner A., Mohle-Boetani J., Lambert R.E. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax 1991; 46: 205-207.

107. Yamacado S., Yoshida Y., Yamada T. et al. Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature. Intern. Med. 1992; 31: 108-113.


Для цитирования:


Муравьев Ю.В., Удельнова И.А. Легочные побочные действия, вызываемые антиревматическими препаратами. Пульмонология. 2003;(4):108-114.

For citation:


Muraviev Yu.V., Udelnova I.A. Adverse effects on the lung caused by anti-rheumatic drugs. PULMONOLOGIYA. 2003;(4):108-114. (In Russ.)

Просмотров: 15


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)